Comparison of therapeutic effects of Azitromaycin and cotrimoxazole in patients with ocular toxoplasmosis .
Phase 3
- Conditions
- ocular toxoplasmosis.Toxoplasma Oculopathy
- Registration Number
- IRCT201401299820N5
- Lead Sponsor
- Tehran University of Medical Sciences, Farabi Eye Hospital, Farabi Eye Reaserch Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
patients with diagnosis of ocular toxoplasmosis with positive serologic test; patients older than 16 years old; no underline diseases(such as diabetic retinopathy or uveitis).
Exclusion criteria: patients under 16 years old; any related systemic or ocular diseases in particular immunodeficiency diseases.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Sharpening of Lesion Border. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Clinical Examination, Fundus Photography.;Lesion Size. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Autoflurescence, Infrared (Image J).;Drug Side Effects. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: CBC diff, Billi (T, D).;Response to Treatment. Timepoint: weeks 3 - 4. Method of measurement: Clinical Examination.;Vissual Improvment. Timepoint: 0, weeks 3 to 4, end of treatment. Method of measurement: Snellen chart.
- Secondary Outcome Measures
Name Time Method Intera ocular Pressure. Timepoint: weeks 0,2 and end of treatment. Method of measurement: goldman tonometery.;Vitritis. Timepoint: weeks 0,2 and end of treatment. Method of measurement: fundus photography and clinical examination.